Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC ...
A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...
Morning Overview on MSN
New bowel cancer approach keeps disease at bay for 3 years
Every patient enrolled in a groundbreaking rectal cancer trial has remained disease-free for more than three years after ...
Two studies presented at the meeting showed the potential of D3 Bio's next-gen KRAS (OFF) inhibitor and Revolution Medicine's novel KRAS (ON) inhibitor.
Patients were given up to 9 weeks of pembrolizumab prior to surgery, instead of the usual surgery followed by 3 to 6 months ...
Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely ...
ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer -- Commercial availability achieved within two months of announcing MENA ...
Immunotherapy—particularly PD-1 inhibition with cemiplimab—is reshaping CSCC care by expanding into neoadjuvant and adjuvant ...
The management of cutaneous squamous cell carcinoma (CSCC) is undergoing a notable shift, with systemic immunotherapy playing ...
This segment highlights the role of clinical guidelines in shaping treatment decisions in advanced melanoma, particularly ...
Switching from IV to subcutaneous injection eases hard vein access, cuts clinic time, and boosts comfort with faster ...
Thai researchers unveil affordable immunotherapy cancer drug, aiming to cut costs and expand access for patients nationwide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results